| scholarly article | Q13442814 |
| P356 | DOI | 10.1056/NEJMC1413918 |
| P698 | PubMed publication ID | 26789901 |
| P50 | author | Joanna von Hofsten | Q92621219 |
| P2093 | author name string | Madeleine Zetterberg | |
| Marianne Johnsson Forsberg | |||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Cytomegalovirus | Q6946 |
| patient | Q181600 | ||
| cytomegalovirus retinitis | Q4271835 | ||
| P304 | page(s) | 296-297 | |
| P577 | publication date | 2016-01-01 | |
| P1433 | published in | The New England Journal of Medicine | Q582728 |
| P1476 | title | Cytomegalovirus Retinitis in a Patient Who Received Ruxolitinib. | |
| P478 | volume | 374 |
| Q38831003 | A novel therapeutic paradigm for patients with extensive alopecia areata |
| Q26740385 | CMV in Hematopoietic Stem Cell Transplantation |
| Q52721155 | Epidemiology, outcome, and risk factors for infectious complications in myelofibrosis patients receiving ruxolitinib: A multicenter study on 446 patients. |
| Q42360482 | Epstein-Barr virus gastric ulcer associated with ruxolitinib |
| Q97566162 | Guidelines for therapy of patients with chronic myeloproliferative neoplasms during the novel coronavirus SARS-CoV2 pandemic |
| Q96690572 | Impaired Virus-Specific T Cell Responses in Patients with Myeloproliferative Neoplasms Treated with Ruxolitinib |
| Q91283883 | Infections associated with immunotherapeutic and molecular targeted agents in hematology and oncology. A position paper by the European Conference on Infections in Leukemia (ECIL) |
| Q47564349 | Infectious complications in patients on treatment with Ruxolitinib: case report and review of the literature |
| Q38684435 | JAK2 inhibitors for myeloproliferative neoplasms: what is next? |
| Q97646648 | Less Can Be More When Targeting Interleukin-6-Mediated Cytokine Release Syndrome in Coronavirus Disease 2019 |
| Q89978571 | Ocular Manifestations in Patients with Philadelphia-Negative Myeloproliferative Neoplasms |
| Q39015300 | Primary myelofibrosis: 2017 update on diagnosis, risk-stratification, and management |
| Q39008738 | Reactivation of Pulmonary Tuberculosis following Treatment of Myelofibrosis with Ruxolitinib |
| Q38938526 | Ruxolitinib in myelofibrosis: to be or not to be an immune disruptor. |
| Q48278553 | Ruxolitinib-associated infections: A systematic review and meta-analysis. |
| Q97416174 | The potential of JAK/STAT pathway inhibition by ruxolitinib in the treatment of COVID-19 |
| Q54611168 | Use of rifampin for treatment of disseminated tuberculosis in a patient with primary myelofibrosis on ruxolitinib. |
| Q45330374 | Varicella-zoster virus meningoencephalitis in a patient treated with ruxolitinib. |
Search more.